翻訳と辞書 |
Tcelna
Tcelna (formerly known as "Tovaxin") is a novel anti-T cell therapeutic vaccine with potential use in treating multiple sclerosis (MS), being developed by Opexa Therapeutics (formerly known as PharmaFrontiers) in The Woodlands, Texas. ==Method of Action== The proposed mechanism parallels that of autologous cancer vaccines, but instead of modifying cancerous cells, Tcelna consists of attenuated autoreactive T cells. The production of the vaccine takes a patient's own T cells from a blood sample; attenuation of the cells during the vaccine production process renders the cells non-replicating but viable. They will elicit an immune response when injected subcutaneously into the patient, with the immune response directed against those T cells within the patient that are self-reactive with myelin, the sheath that covers the neurons affected in multiple sclerosis. It is hoped that this immune response directed against a specific subset of autoreactive T cells might reduce the number of these autoreactive cells in MS patients.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Tcelna」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|